Brief: Carisma Therapeutics Announces Nomination Of First In Vivo Car-M Development Candidate For Hepatocellular Carcinoma Under Collaboration With Moderna
27/06/2024 21:34
Carisma Therapeutics Inc CARM.O :
* CARISMA THERAPEUTICS ANNOUNCES NOMINATION OF FIRST IN VIVO
CAR-M
DEVELOPMENT CANDIDATE FOR HEPATOCELLULAR CARCINOMA UNDER
COLLABORATION WITH MODERNA
* CARISMA THERAPEUTICS INC -NOMINATION TRIGGERS A $2 MILLION
MILESTONE PAYMENT TO CARISMA
* CARISMA THERAPEUTICS INC - IN ADDITION TO THIS PROGRAM,
MODERNA
HAS NOMINATED FOUR UNDISCLOSED ONCOLOGY RESEARCH TARGETS UNDER
COLLABORATION
Source text for Eikon: ID:nPn8KdYM1a
Further company coverage: CARM.O
Recent news on Carisma Therapeutics
See all newsBrief: Carisma Therapeutics & Modernatx Amend Collaboration & And License Agreement - SEC Filing
Carisma Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Carisma Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Carisma Therapeutics And Orthocellix Enter Into Definitive Merger Agreement
Carisma Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary